These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 28930171)

  • 41. Prognostic impact of SUMO-specific protease 1 (SENP1) in prostate cancer patients undergoing radical prostatectomy.
    Li T; Huang S; Dong M; Gui Y; Wu D
    Urol Oncol; 2013 Nov; 31(8):1539-45. PubMed ID: 23089540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aberrant methylation of protocadherin 17 and its clinical significance in patients with prostate cancer after radical prostatectomy.
    Lin YL; Xie PG; Wang L; Ma JG
    Med Sci Monit; 2014 Aug; 20():1376-82. PubMed ID: 25091018
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
    Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
    J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Plasma levels of trefoil factors are increased in patients with advanced prostate cancer.
    Vestergaard EM; Borre M; Poulsen SS; Nexø E; Tørring N
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):807-12. PubMed ID: 16467092
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of the clinical value of the newly identified urine biomarker HIST1H4K for diagnosis and prognosis of prostate cancer in Bulgarian patients.
    Kachakova D; Mitkova A; Popov E; Beltcheva O; Vlahova A; Dikov T; Hristova S; Mitev V; Slavov C; Kaneva R
    J BUON; 2013; 18(3):660-8. PubMed ID: 24065480
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Promoter methylation of MCAM, ERα and ERβ in serum of early stage prostate cancer patients.
    Brait M; Banerjee M; Maldonado L; Ooki A; Loyo M; Guida E; Izumchenko E; Mangold L; Humphreys E; Rosenbaum E; Partin A; Sidransky D; Hoque MO
    Oncotarget; 2017 Feb; 8(9):15431-15440. PubMed ID: 28147335
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Downregulation of miR-129 in peripheral blood mononuclear cells is a diagnostic and prognostic biomarker in prostate cancer.
    Xu S; Yi XM; Zhou WQ; Cheng W; Ge JP; Zhang ZY
    Int J Clin Exp Pathol; 2015; 8(11):14335-44. PubMed ID: 26823749
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparing diagnostic and prognostic performance of two-gene promoter methylation panels in tissue biopsies and urines of prostate cancer patients.
    Moreira-Barbosa C; Barros-Silva D; Costa-Pinheiro P; Torres-Ferreira J; Constâncio V; Freitas R; Oliveira J; Antunes L; Henrique R; Jerónimo C
    Clin Epigenetics; 2018 Oct; 10(1):132. PubMed ID: 30373654
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DNA methylation screening of primary prostate tumors identifies SRD5A2 and CYP11A1 as candidate markers for assessing risk of biochemical recurrence.
    Horning AM; Awe JA; Wang CM; Liu J; Lai Z; Wang VY; Jadhav RR; Louie AD; Lin CL; Kroczak T; Chen Y; Jin VX; Abboud-Werner SL; Leach RJ; Hernandez J; Thompson IM; Saranchuk J; Drachenberg D; Chen CL; Mai S; Huang TH
    Prostate; 2015 Nov; 75(15):1790-801. PubMed ID: 26332453
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Prognostic significance of aberrantly silenced ANPEP expression in prostate cancer.
    Sørensen KD; Abildgaard MO; Haldrup C; Ulhøi BP; Kristensen H; Strand S; Parker C; Høyer S; Borre M; Ørntoft TF
    Br J Cancer; 2013 Feb; 108(2):420-8. PubMed ID: 23322201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparative analysis of epi-miRNA expression levels in local/locally advanced and metastatic prostate cancer patients.
    Gurbuz V; Kiliccioglu I; Dikmen AU; Bilen CY; Sozen S; Konac E
    Gene; 2020 Oct; 758():144963. PubMed ID: 32683077
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Downregulation of zinc finger protein 132 in prostate cancer is associated with aberrant promoter hypermethylation and poor prognosis.
    Abildgaard MO; Borre M; Mortensen MM; Ulhøi BP; Tørring N; Wild P; Kristensen H; Mansilla F; Ottosen PD; Dyrskjøt L; Ørntoft TF; Sørensen KD
    Int J Cancer; 2012 Feb; 130(4):885-95. PubMed ID: 21445975
    [TBL] [Abstract][Full Text] [Related]  

  • 53. DLEC1, a 3p tumor suppressor, represses NF-κB signaling and is methylated in prostate cancer.
    Zhang L; Zhang Q; Li L; Wang Z; Ying J; Fan Y; He Q; Lv T; Han W; Li J; Yang Y; Xu B; Wang L; Liu Q; Sun Y; Guo Y; Tao Q; Jin J
    J Mol Med (Berl); 2015 Jun; 93(6):691-701. PubMed ID: 25648635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 55. Development and clinical validation of a real-time PCR assay for PITX2 DNA methylation to predict prostate-specific antigen recurrence in prostate cancer patients following radical prostatectomy.
    Dietrich D; Hasinger O; Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Wernert N; Perner S; Freedland SJ; Corman JM; Ittmann MM; Lark AL; Madden JF; Hartmann A; Schatz P; Kristiansen G
    J Mol Diagn; 2013 Mar; 15(2):270-9. PubMed ID: 23266319
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    Barry KH; Mohanty K; Erickson PA; Wang D; Shi J; Rose G; Cellini A; Clark K; Ambulos N; Yin J; Yan L; Poulin M; Meyer A; Zhang Y; Bentzen SM; Burke A; Hussain A; Berndt SI
    Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.
    Møller M; Strand SH; Mundbjerg K; Liang G; Gill I; Haldrup C; Borre M; Høyer S; Ørntoft TF; Sørensen KD
    Sci Rep; 2017 Jan; 7():40636. PubMed ID: 28084441
    [TBL] [Abstract][Full Text] [Related]  

  • 58. ZNF154 is a promising diagnosis biomarker and predicts biochemical recurrence in prostate cancer.
    Zhang W; Shu P; Wang S; Song J; Liu K; Wang C; Ran L
    Gene; 2018 Oct; 675():136-143. PubMed ID: 29966681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HOXB13 and TFF3 can contribute to the prognostic stratification of prostate adenocarcinoma.
    Timofte AD; Giuşcă SE; Lozneanu L; Manole MB; Prutianu I; Gafton B; Rusu A; Căruntu ID
    Rom J Morphol Embryol; 2021; 62(1):41-52. PubMed ID: 34609407
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
    Tsourlakis MC; Eleftheriadou A; Stender A; Weigand P; Grupp K; Hube-Magg C; Kluth M; Schroeder C; Steurer S; Hinsch A; Luebke A; Angerer A; Wittmer C; Friedrich E; Göbel C; Büscheck F; Heinzer H; Graefen M; Simon R; Sauter G; Wilczak W; Minner S; Schlomm T; Jacobsen F
    Carcinogenesis; 2017 Dec; 38(12):1180-1187. PubMed ID: 29029032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.